Agency for Care Effectiveness - ACE

Agency for Care Effectiveness - ACE ACE is the national health technology assessment (HTA) and clinical guidance agency in Singapore. What We Do


I. II. III. IV.

Welcome to the official page of the Agency for Care Effectiveness (ACE). Established by the Ministry of Health, the Agency for Care Effectiveness (ACE) is the national Health Technology Assessment (HTA) and Clinical Guidance Agency in Singapore. We support providers, patients, and payers make better-informed decisions about patient care. We achieve this by conducting health technology ass

essments (HTAs), publishing healthcare guidances and providing education. HTA

Established by the Ministry of Health in 2015, we are the national HTA agency in Singapore. We conduct technical evaluations that inform funding decisions for health technologies, and drive their appropriate use by:

• Publishing technology guidances on the clinical effectiveness, safety, and cost-effectiveness of health technologies;
• Conducting value-based pricing negotiations with manufacturers to ensure that prices of patented health technologies are commensurate with the outcomes they deliver for patients and the Singapore health system;
• Tracking utilisation and outcomes related to funded health technologies to study the impact of funding decisions;
• Developing and implementing adoption strategies within public healthcare institutions to drive uptake of technology guidances. Clinical Guidance

We develop and publish clinical guidances that provide concise, evidence-based recommendations to inform specific areas of clinical practice. Healthcare Professional Education

We assist healthcare professionals to apply the best available evidence in their practice through collaborative continuing professional education. Healthcare Consumer Education

We provide information and tools for patients and caregivers to help them find out more about different medical conditions and treatment options, and to take part in shared decision-making with their clinicians about their healthcare needs. Find out more about our work at https://www.ace-hta.gov.sg/campaign/

-

Social Media Terms of Use

We encourage all visitors on our page to start conversations and share with us your thoughts, suggestions, and comments, if any. While we welcome constructive discussions, and want everyone’s experience to be positive, please note that any offensive posts or comments will be removed, and users that repeatedly breach the terms of use may also be blocked from this page. As social media is not a platform for clinical advice – please get in touch with your pharmacist or doctor regarding medical queries. Out of respect for users of our page, ACE reserves the right to remove any comments or posts of the following nature:
- Abusive, vulgar, obscene, violent or defamatory language
- Hateful or discriminatory remarks towards any specific groups or individuals
- Advertising, promotion or endorsement of any products, services or brands
- Fraudulent, inaccurate, non-evidence based information, including spam
- Violation of any copyright, contains proprietary or personal information (email addresses, phone numbers, account numbers etc.)
- Any other comments or posts that breach Facebook’s Term of Service of Community Standards.

27/05/2026

Selamat Hari Raya Haji ✨

From all of us at ACE, we wish those celebrating a meaningful and peaceful Hari Raya Haji.

May this occasion bring reflection and a renewed sense of purpose, as we continue working together to improve care for all.

17/05/2026

Hypertension is often called a “silent” condition — but its effects are far from invisible.

In Singapore, more than 1 in 3 adults has hypertension, and over half remain undiagnosed. If left unmanaged, it can lead to serious complications such as stroke, heart disease, and kidney damage.

Managing hypertension involves more than just lowering blood pressure. It includes understanding overall cardiovascular risk and taking appropriate steps — from lifestyle changes to treatment where needed.

👉 This World Hypertension Day, read our ACG on hypertension here: https://go.gov.sg/acefb311

13/05/2026

🎉We are pleased to share that ACE has published two articles in the International Journal of Technology Assessment in Health Care, highlighting Singapore's journey in strengthening patient involvement in health technology assessment (HTA)!

📄The first publication - "Patient involvement in health technology assessment: a new process in Singapore" describes ACE’s approach to identifying relevant local patient organisations through stakeholder mapping, co-developing processes with these organisations, and building capacity to support meaningful patient input.

📄The second publication - "Establishing a Consumer Panel to Inform Health Technology Assessment Processes and Policy: impact and insights from Singapore's experience", outlines ACE's approach to establishing the Consumer Panel and highlights its contributions. These include co-developing patient involvement processes and educational resources, supporting health literacy efforts, and strengthening collaboration between ACE and patient communities. Panel members Prof Lau Tang Ching and Dr Ritu Jain also contributed to this article as co-authors.

These publications demonstrate ACE’s ongoing efforts to strengthen patient voices in healthcare decision-making.

Click the links below to read the full articles:

1. https://go.gov.sg/acefb308

2. https://go.gov.sg/acefb309

Find out more about how you can contribute to ACE’s work: https://go.gov.sg/acefb310

12/05/2026

📖 Our latest CEE Updates is now available! We are excited to share that ACE has published two articles in the International Journal of Technology Assessment in Health Care, featuring patient involvement in the health technology assessment (HTA) processes in Singapore, as well as the establishment of the ACE Consumer Panel and its contributions.

📚 We have also developed two new HTA learning modules to help patients better understand clinical effectiveness and the PICO framework. New patient education aids and Plain English summaries are also available to make healthcare information more accessible.

🌟 Last but not least, we extend our sincere thanks to the ACE Consumer Panel members for strengthening patient voices in healthcare decision-making. Through shaping ACE’s patient involvement initiatives and helping us build meaningful partnerships between patients and healthcare decision-makers, your contributions have been invaluable. We look forward to continuing our work together to improve healthcare in Singapore.

Read more about our recent educational resources and patient engagement activities in our latest CEE Updates: https://go.gov.sg/acefb307

01/05/2026

Living with atopic dermatitis? This common skin condition affects people of all ages, causing dry, itchy patches that can be frustrating to manage.

The good news? With the right approach - such as gentle moisturising routines and using prescribed treatments when needed - many people are able to keep their symptoms under control.

But we know you might still be wondering:

•Can I still enjoy swimming?
•Are there foods I should avoid?
•How can I prevent flare-ups?

Get answers to these questions in our latest patient education aid on atopic dermatitis: https://go.gov.sg/acefb305

21/04/2026

As the ACE Consumer Panel completes its two-year term (2024-2026), we would like to express our heartfelt gratitude for the Panel’s contributions to strengthening patient involvement in health technology assessment (HTA) in Singapore.

Through their expertise, insights, and commitment, the Panel has helped shape ACE's consumer engagement initiatives and ensure that patient voices are heard in healthcare decision-making.

We thank all Panel members for their partnership in advancing meaningful patient involvement. We look forward to continuing to involve patients and their carers in HTA in the years ahead.

🎥 Watch our appreciation video to see highlights from the past two years.

Find out more about how patients and carers can contribute to the HTA process in Singapore: https://go.gov.sg/acefb303

Living with haemophilia B: Mr T’s storyHaemophilia B is an inherited bleeding disorder where the blood does not clot pro...
20/04/2026

Living with haemophilia B: Mr T’s story

Haemophilia B is an inherited bleeding disorder where the blood does not clot properly due to low levels of factor IX – a protein essential for blood clotting. As a result, individuals with haemophilia B bleed for longer than usual and may experience prolonged bleeding after injury or surgery, as well as internal bleeding into muscles and joints.

Mr T was diagnosed with severe haemophilia B as a child and experienced frequent muscle and joint bleeds, which affected his ability to participate in daily activities. Over time, these bleeding episodes led to missed days from school and work and caused long-term strain on his joints.

Following an evidence-based evaluation by the Agency for Care Effectiveness (ACE), the MOH Drug Advisory Committee (DAC) recommended a recombinant factor IX product for subsidy under the MOH Standard Drug List (SDL). MediShield Life coverage was also expanded to include treatments for haemophilia that are clinically proven and cost-effective, helping make prophylactic treatment more affordable for eligible patients.

These changes enabled Mr T to access regular recombinant factor IX prophylaxis, reducing breakthrough bleeds and supporting his ability to stay active at work and in daily life.

Learn more about haemophilia and its treatments with our factsheet: https://go.gov.sg/acefb304

Since MOH’s Circular on the Diagnosis and Management of Dengue Fever (DF) / Dengue Haemorrhagic Fever (DHF) in 2015, new...
08/04/2026

Since MOH’s Circular on the Diagnosis and Management of Dengue Fever (DF) / Dengue Haemorrhagic Fever (DHF) in 2015, new evidence for the treatment and management of dengue have emerged. The new Singapore National Dengue Guideline, developed by NCID, provides clinicians with updated evidence-based recommendations and incorporates recent research and best practices to support dengue management in Singapore.

Asst Prof Chia Po Ying, Head of NCID Research and Senior Consultant at the Department of Infectious Disease (NCID/TTSH), who chairs the NCID-led Dengue Guidelines Workgroup, shares how these updated guidelines will support clinical decision-making and improve patient care in dengue management.

The dengue guideline has been methodologically validated by ACE as meeting ACE’s Guidelines for Guidelines (G4G) standards for high-quality clinical guideline development.

Read the guideline now at https://go.gov.sg/aceli422

07/04/2026

🌍 This World Health Day, we are reminded that better health outcomes start with good evidence.

At ACE, we review clinical evidence and conduct Health Technology Assessments (HTA) to inform healthcare decisions in Singapore — from subsidy decisions to clinical guidance.
Our work helps ensure that patients receive treatments that are safe, clinically effective and cost-effective, and that healthcare resources are used where they make the most difference.

By translating scientific evidence into action, ACE supports more accessible and affordable care for Singaporeans.

23/01/2026

Immunotherapy is one of the treatment options for advanced non-small cell lung cancer (NSCLC) and several immunotherapy drugs are subsidised in Singapore for this condition.

Learn more about immunotherapy drugs for advanced NSCLC in our latest factsheet: go.gov.sg/acefb295

Address

College Of Medicine Building, 16 College Road
Singapore
169854

Website

Alerts

Be the first to know and let us send you an email when Agency for Care Effectiveness - ACE posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Agency for Care Effectiveness - ACE:

Shortcuts

Share

Category